We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Bristol-Myers Squibb Company (NYSE:BMY) ...
The proposed changes are relatively modest, yet they represent an important procedural step forward in the implementation of ...
On June 16, 2025, the Centers for Medicare & Medicaid Services (CMS) issued a proposed rule, “Medicare Drug Price Negotiation Program and ...
John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. WASHINGTON — The Trump ...
The One Big Beautiful Bill Act removed a number of orphan drugs from being subject to price negotiations, and this could cost the Medicare program $8.8 billion over the course of about 10 years. That ...
The U.S. Court of Appeals for the Third Circuit has rejected an IRA price negotiation lawsuit from Novartis, seven days after doing the same on an appeal from Bristol Myers Squibb and Johnson & ...
John writes about the politics of health care, and he is the author of the twice-weekly D.C. Diagnosis newsletter. You can reach John on Signal at John_Wilkerson.07. WASHINGTON — President Trump may ...
Permanent rulemaking would replace IPAY 2026–2028 guidance, enabling predictable annual negotiations of up to 20 drugs and defined manufacturer agreement and renegotiation requirements. Formularies ...
“There is no protected property interest in selling goods to Medicare beneficiaries…at a price higher than what the government is willing to pay when it reimburses those costs.” – District Court for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results